Cetuximab (Erbitux®) for the treatment of metastatic colorectal cancer

The National Health Care Institute has carried out a re-assessment of the medicinal product cetuximab (Erbitux®), whereby they came to the conclusion that, for the assessed indication, cetuximab a therapeutic added value has in comparison with FOLFOX alone.

This report is a summary of recommendations by the National Health Care Institute. The original text is in Dutch.